Skip to main content
Top
Published in: International Journal of Hematology 1/2016

01-01-2016 | Original Article

Combined prognostic value of absolute lymphocyte/monocyte ratio in peripheral blood and interim PET/CT results in Hodgkin lymphoma

Authors: Zsofia Simon, S. Barna, Z. Miltenyi, K. Husi, F. Magyari, A. Jona, I. Garai, Z. Nagy, G. Ujj, L. Szerafin, A. Illes

Published in: International Journal of Hematology | Issue 1/2016

Login to get access

Abstract

Decreased absolute lymphocyte/monocyte ratio (LMR) in peripheral blood has been reported as an unfavorable prognostic marker in Hodgkin lymphoma. We aimed to investigate whether combining LMR and interim PET/CT scan result (PET2) confers stronger prognostic value than PET2 alone. 121 HL patients were investigated. LMR was calculated from a blood sample taken at the time of diagnosis. PET2 was carried out after the second chemotherapy cycle. Survival was calculated using the Kaplan–Meier method and significance was determined by log-rank test. Effect of variants on survival results was examined using univariate and multivariate analyses. Best LMR cut-off value was determined by receiver operating characteristic (ROC) curve. Best LMR cut-off value was 2.11 in the case of our patients (LMR >2.11: favorable, LMR ≤2.11: unfavorable). Overall and progression-free survivals (OS/PFS) were significantly worse both in lower LMR (≤2.11) (OS: P = 0.041, PFS: P = 0.044) and PET2 positive groups (OS: P < 0.001, PFS: P < 0.001). In PET2 positive patient group (n = 32) the low LMR result meant a significantly worse OS (0.030) and PFS (0.001). Both LMR and PET2 proved to be independent prognostic factors on multivariate analysis, and strengthened each other’s effect.
Literature
1.
go back to reference Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M, et al. Early interim 2-[18F]fluoro-2-deoxy-d-glucose positron emission tomography is prognostically superior to International Prognostic Score in advanced-stage Hodgkin’s lymphoma: a report from a Joint Italian-Danish study. J Clin Oncol. 2007;25:3746–52.PubMedCrossRef Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M, et al. Early interim 2-[18F]fluoro-2-deoxy-d-glucose positron emission tomography is prognostically superior to International Prognostic Score in advanced-stage Hodgkin’s lymphoma: a report from a Joint Italian-Danish study. J Clin Oncol. 2007;25:3746–52.PubMedCrossRef
2.
go back to reference Kostakoglu L, Cheson BD. State-of-the-art research on “lymphomas: role of molecular imaging for staging, prognostic evaluation, and treatment response”. Front Oncol. 2013;3:1–9.CrossRef Kostakoglu L, Cheson BD. State-of-the-art research on “lymphomas: role of molecular imaging for staging, prognostic evaluation, and treatment response”. Front Oncol. 2013;3:1–9.CrossRef
3.
go back to reference Gallamini A, Barrington SF, Biggi A, Chauvie S, Kostakoglu L, Gregianin M, et al. The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale. Haematologica. 2014;99:1107–13.PubMedPubMedCentralCrossRef Gallamini A, Barrington SF, Biggi A, Chauvie S, Kostakoglu L, Gregianin M, et al. The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale. Haematologica. 2014;99:1107–13.PubMedPubMedCentralCrossRef
4.
go back to reference Koh YW, Kang HJ, Park C, Yoon DH, Kim S, Suh C, et al. The ratio of the absolute lymphocyte count to the absolute monocyte count is associated with prognosis in Hodgkin’s lymphoma: correlation with tumor-associated macrophages. Oncologist. 2012;17:871–80.PubMedPubMedCentralCrossRef Koh YW, Kang HJ, Park C, Yoon DH, Kim S, Suh C, et al. The ratio of the absolute lymphocyte count to the absolute monocyte count is associated with prognosis in Hodgkin’s lymphoma: correlation with tumor-associated macrophages. Oncologist. 2012;17:871–80.PubMedPubMedCentralCrossRef
5.
go back to reference Porrata LF, Ristow K, Colgan JP, Habermann TM, Witzig TE, Inwards DJ, et al. Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin’s lymphoma. Haematologica. 2012;97:262–9.PubMedPubMedCentralCrossRef Porrata LF, Ristow K, Colgan JP, Habermann TM, Witzig TE, Inwards DJ, et al. Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin’s lymphoma. Haematologica. 2012;97:262–9.PubMedPubMedCentralCrossRef
6.
go back to reference Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin’s disease. International prognostic factors project on advanced Hodgkin’s disease. N Eng J Med. 1998;339:1506–14.CrossRef Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin’s disease. International prognostic factors project on advanced Hodgkin’s disease. N Eng J Med. 1998;339:1506–14.CrossRef
7.
go back to reference Jakovic LR, Andjelic BM, Bogdanovic AD, Babic D, Bumbasirevic VZ, Mihaljevic BS. Peripheral blood lymphocyte/monocyte ratio in advanced stage classical Hodgkin lymphoma: prognostic value and correlation with IPS and tumor associated macrophages. Haematologica. 2013;s2:5 (abstract: P014). Jakovic LR, Andjelic BM, Bogdanovic AD, Babic D, Bumbasirevic VZ, Mihaljevic BS. Peripheral blood lymphocyte/monocyte ratio in advanced stage classical Hodgkin lymphoma: prognostic value and correlation with IPS and tumor associated macrophages. Haematologica. 2013;s2:5 (abstract: P014).
8.
go back to reference Barrington SF, Qian W, Somer EJ, Franceschetto A, Bagni B, Brun E, et al. Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging. 2010;37:1824–33.PubMedCrossRef Barrington SF, Qian W, Somer EJ, Franceschetto A, Bagni B, Brun E, et al. Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging. 2010;37:1824–33.PubMedCrossRef
9.
go back to reference Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–86.PubMedCrossRef Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–86.PubMedCrossRef
10.
go back to reference Terasawa T, Lau J, Bardet S, Couturier O, Hotta T, Hutchings M, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin’s lymphoma and diffuse large B-cell lymphoma: a systematic review. J Clin Oncol. 2009;27:1906–14.PubMedCrossRef Terasawa T, Lau J, Bardet S, Couturier O, Hotta T, Hutchings M, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin’s lymphoma and diffuse large B-cell lymphoma: a systematic review. J Clin Oncol. 2009;27:1906–14.PubMedCrossRef
11.
go back to reference Sauer M, Plütschow A, Jachimowicz RD, Kleefisch D, Reiners KS, Ponader S, et al. Baseline serum TARC levels predict therapy outcome in patients with Hodgkin lymphoma. Am J Hematol. 2013;88:113–5.PubMedCrossRef Sauer M, Plütschow A, Jachimowicz RD, Kleefisch D, Reiners KS, Ponader S, et al. Baseline serum TARC levels predict therapy outcome in patients with Hodgkin lymphoma. Am J Hematol. 2013;88:113–5.PubMedCrossRef
12.
go back to reference Jones K, Vari F, Keane C, Crooks P, Nourse JP, et al. Serum CD163 and TARC as disease response biomarkers in classical Hodgkin lymphoma. Clin Cancer Res. 2012;19:731–42.PubMedCrossRef Jones K, Vari F, Keane C, Crooks P, Nourse JP, et al. Serum CD163 and TARC as disease response biomarkers in classical Hodgkin lymphoma. Clin Cancer Res. 2012;19:731–42.PubMedCrossRef
13.
go back to reference Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, et al. Tumor-associated macrophages and survival in classic Hodgkin’s lymphoma. N Engl Med. 2010;362:875–85.CrossRef Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, et al. Tumor-associated macrophages and survival in classic Hodgkin’s lymphoma. N Engl Med. 2010;362:875–85.CrossRef
14.
go back to reference Jakovic LR, Mihaljevic BS, Perunicic J, Bogdanovic AD, Andjelic BM, Bumbasirevic VZ. The prognostic relevance of tumor associated macrophages in advanced stage classical Hodgkin lymphoma. Leuk Lymphoma. 2011;52:1913–9.PubMedCrossRef Jakovic LR, Mihaljevic BS, Perunicic J, Bogdanovic AD, Andjelic BM, Bumbasirevic VZ. The prognostic relevance of tumor associated macrophages in advanced stage classical Hodgkin lymphoma. Leuk Lymphoma. 2011;52:1913–9.PubMedCrossRef
15.
go back to reference Gulherme R, Santos M, Silva R. Peripheral blood lymphocyte/monocyte ratio at diagnosis as a prognostic factor of survival in classic Hodgkin lymphoma, poster no. 1057. In: 19th annual meeting of the European Hematology Association, 14 June 2014, Milan. Gulherme R, Santos M, Silva R. Peripheral blood lymphocyte/monocyte ratio at diagnosis as a prognostic factor of survival in classic Hodgkin lymphoma, poster no. 1057. In: 19th annual meeting of the European Hematology Association, 14 June 2014, Milan.
16.
go back to reference Porrata LF, Ristow KM, Habermann TM, Witzig TE, Colgan JP, Inwards DJ, et al. Absolute lymphocyte/monocyte ratio at diagnosis and interim positron-emission tomography predict survival in classical Hodgkin lymphoma. J Cancer Ther. 2013;4:452–9.CrossRef Porrata LF, Ristow KM, Habermann TM, Witzig TE, Colgan JP, Inwards DJ, et al. Absolute lymphocyte/monocyte ratio at diagnosis and interim positron-emission tomography predict survival in classical Hodgkin lymphoma. J Cancer Ther. 2013;4:452–9.CrossRef
17.
go back to reference Romano A, Vetro C, Donnarumma D, Forte S, Ippolito M, Di Raimondo F. Early interim 2-(1)Fluoro-2-deoxy-d-glucose positron emission tomography is prognostically superior to peripheral blood lymphocyte/monocyte ratio at diagnosis in classical Hodgkin’s lymphoma. Haematologica. 2012;97:e22–3.CrossRef Romano A, Vetro C, Donnarumma D, Forte S, Ippolito M, Di Raimondo F. Early interim 2-(1)Fluoro-2-deoxy-d-glucose positron emission tomography is prognostically superior to peripheral blood lymphocyte/monocyte ratio at diagnosis in classical Hodgkin’s lymphoma. Haematologica. 2012;97:e22–3.CrossRef
Metadata
Title
Combined prognostic value of absolute lymphocyte/monocyte ratio in peripheral blood and interim PET/CT results in Hodgkin lymphoma
Authors
Zsofia Simon
S. Barna
Z. Miltenyi
K. Husi
F. Magyari
A. Jona
I. Garai
Z. Nagy
G. Ujj
L. Szerafin
A. Illes
Publication date
01-01-2016
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 1/2016
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-015-1884-z

Other articles of this Issue 1/2016

International Journal of Hematology 1/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine